Back to Search
Start Over
Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort
- Source :
- The European Journal of Health Economics
- Publication Year :
- 2016
- Publisher :
- Springer Science and Business Media LLC, 2016.
-
Abstract
- Background Diffuse large B-cell lymphoma (DLBCL) is the commonest non-Hodgkin lymphoma. Previous studies examining the cost of treating DLBCL have generally focused on a specific first-line therapy alone; meaning that their findings can neither be extrapolated to the general patient population nor to other points along the treatment pathway. Based on empirical data from a representative population-based patient cohort, the objective of this study was to develop a simulation model that could predict costs and life expectancy of treating DLBCL. Methods All patients newly diagnosed with DLBCL in the UK’s population-based Haematological Malignancy Research Network (www.hmrn.org) in 2007 were followed until 2013 (n = 271). Mapped treatment pathways, alongside cost information derived from the National Tariff 2013/14, were incorporated into a patient-level simulation model in order to reflect the heterogeneities of patient characteristics and treatment options. The NHS and social services perspective was adopted, and all outcomes were discounted at 3.5 % per annum. Results Overall, the expected total medical costs were £22,122 for those treated with curative intent, and £2930 for those managed palliatively. For curative chemotherapy, the predicted medical costs were £14,966, £23,449 and £7376 for first-, second- and third-line treatments, respectively. The estimated annual cost for treating DLBCL across the UK was around £88–92 million. Conclusions This is the first cost modelling study using empirical data to provide ‘real world’ evidence throughout the DLBCL treatment pathway. Future application of the model could include evaluation of new technologies/treatments to support healthcare decision makers, especially in the era of personalised medicine. Electronic supplementary material The online version of this article (doi:10.1007/s10198-016-0775-4) contains supplementary material, which is available to authorized users.
- Subjects :
- Male
Time Factors
Economics, Econometrics and Finance (miscellaneous)
State Medicine
0302 clinical medicine
hemic and lymphatic diseases
Health care
health care economics and organizations
Aged, 80 and over
education.field_of_study
Patient-level simulation
I11
030503 health policy & services
Health Policy
Palliative Care
E17
Diffuse large B-cell lymphoma
Middle Aged
030220 oncology & carcinogenesis
Cohort
Costs and Cost Analysis
Female
Lymphoma, Large B-Cell, Diffuse
H43
0305 other medical science
Models, Econometric
Adult
medicine.medical_specialty
Cost
Population
Discrete event simulation
Decision Support Techniques
03 medical and health sciences
Life Expectancy
medicine
Humans
Operations management
education
Intensive care medicine
Aged
Original Paper
Health economics
business.industry
Public health
medicine.disease
United Kingdom
D61
DLBCL
Life expectancy
D24
Observational study
business
Subjects
Details
- ISSN :
- 16187601 and 16187598
- Volume :
- 18
- Database :
- OpenAIRE
- Journal :
- The European Journal of Health Economics
- Accession number :
- edsair.doi.dedup.....5104c546d2f0c4acbd2809bd895728ef
- Full Text :
- https://doi.org/10.1007/s10198-016-0775-4